Key takeaways
Duobrii (halobetasol/tazarotene) and Skyrizi (risankizumab) are both used to treat plaque psoriasis, but they have some key differences. Duobrii is a topical lotion that combines a corticosteroid and a retinoid, while Skyrizi is an injectable interleukin antagonist. Duobrii is applied once daily directly to the skin, whereas Skyrizi is injected under the skin every 2 to 3 months after initial doses. Duobrii can cause skin irritation and sun sensitivity, and it is not recommended for long-term use due to potential hormone changes. On the other hand, Skyrizi can increase the risk of infections and may cause joint pain and headaches. Skyrizi is also used to treat psoriatic arthritis and Crohn's disease, while Duobrii is specifically for plaque psoriasis. Both Duobrii and Skyrizi are only available as a brand-name medication, making them potentially more expensive. Duobrii can be self-applied, whereas Skyrizi is a biologic medication that can be self-administered at home after proper training.
